Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 30, 2013
Boston Scientific Corporation (NYSE:BSX) ha anunciado hoy la primera inscripción en el registro EWOLUTION con la utilización del dispositivo WATCHMAN en la vida real. Se trata de un registro...
-
Oct 28, 2013REDUCE-HTN Data Presented Today at TCT Demonstrate Excellent Safety Profile
Patients treated with the Boston Scientific (NYSE: BSX) Vessix™ Renal Denervation System experienced a significant and sustained reduction in blood pressure, according to new data presented...
-
Oct 28, 2013Il dispositivo per la sostituzione transcatetere della valvola aortica (TAVR, Transcatheter Aortic Valve Replacement) permette il posizionamento preciso, garantendo ai medici una possibilità di controllo senza precedenti
Boston Scientific Corporation (NYSE: BSX) ha ricevuto il marchio CE per la valvola Lotus™, la tecnologia innovativa d e ll'azienda per la sostituzione transcatetere della valvola aortica (TAVR)....
-
Oct 28, 2013
Transcatheter Aortic Valve Replacement (TAVR) Device Offers Precise Positioning and Placement, Offering Physicians Unprecedented Control Boston Scientific Corporation (NYSE: BSX) has received CE...
-
Oct 28, 2013REDUCE-HTN Data Presented Today at TCT Demonstrate Excellent Safety Profile
Patients treated with the Boston Scientific (NYSE: BSX) Vessix™ Renal Denervation System experienced a significant and sustained reduction in blood pressure, according to new data presented...
-
Oct 8, 2013University of Pittsburgh independent study of contemporary heart failure devices highlights industry-leading Boston Scientific battery longevity
An independent and first-of-its-kind study from the University of Pittsburgh Medical Center, published online this week in EP EuroPace, shows there are significant differences in battery longevity...
-
Sep 26, 2013REPRISE-II-Daten wurden im Rahmen des PCR London Valves Course zum "Best Abstract 2013" gekürt
Boston Scientific Corporation (NYSE: BSX) hat die positiven 6-Monats-Daten für die ersten 60 Probanden der klinischen Studie REPRISE II vorgelegt, die die Sicherheit und Effizienz...
-
Sep 25, 2013Boston Scientific comunica i risultati positivi a sei mesi dello studio clinico sulla valvola Lotus™I dati di REPRISE II premiati con il Miglior Abstract 2013 al PCR London Valves Course
La Boston Scientific Corporation (NYSE: BSX) ha comunicato i risultati positivi a sei mesi dei primi 60 pazienti arruolati nello studio clinico REPRISE II che valutava la sicurezza e la...
-
Sep 17, 2013
REPRISE II Data Honored as Best Abstract 2013 at PCR London Valves Course Boston Scientific Corporation (NYSE: BSX) reported favorable six-month results from the first 60 patients enrolled in the...
-
Sep 12, 2013
In a significant milestone toward obtaining additional key regulatory approvals for the SYNERGY™ Stent System, Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the EVOLVE II...
-
Sep 11, 2013A diferencia del tratamiento farmacológico por sí solo, la termoplastia aporta efectos beneficiosos que duran años en lugar de horas
Una novedosa tecnología de Boston Scientific para el tratamiento del asma grave ha demostrado su seguridad y eficacia a lo largo de cinco años, según los da The Journal of Allergy and Clinical...
-
Sep 10, 2013
Langzeitdaten in The Journal of Allergy and Clinical Immunology veröffentlicht: Patienten mit schwerem Asthma profitieren für Jahre von einer nicht-medikamentösen Therapie, wo Medikamente...
-
Sep 9, 2013I benefici comportati dalla termoplastica bronchiale perdurano per anni, anziché per ore, diversamente da quanto accade col solo trattamento farmacologico.
News Newsroom Italia Asma grave Archivio Comunicati Stampa 2013 Sep 09, 2013 Comunicato Stampa The Journal of Allergy and Clinical Immunology pubblica i dati sulla termoplastica bronchiale che...
-
Sep 4, 2013Unlike Medications Alone, Bronchial Thermoplasty Provides Benefits That Last for Years Rather Than Hours
A breakthrough Boston Scientific technology for the treatment of severe asthma has been shown to be safe and effective over at least five years, according to data published online in a key medical...
-
Jul 19, 2013
First Patient Treated in OPTIMISE Clinical Trial Evaluating Safety, Efficacy of Occipital Nerve Stimulation Using Precision™ System Boston Scientific Corporation (NYSE: BSX) has launched a...
-
Jul 19, 2013
First Patient Treated in OPTIMISE Clinical Trial Evaluating Safety, Efficacy of Occipital Nerve Stimulation Using Precision™ System Boston Scientific Corporation (NYSE: BSX) has launched a...
-
Jul 19, 2013Boston Scientific Launches Trial To Evaluate Neurostimulation For Treatment Of Chronic Migraine [EN]First Patient Treated in OPTIMISE Clinical Trial Evaluating Safety, Efficacy of Occipital Nerve Stimulation Using Precision™ System
Boston Scientific Corporation (NYSE: BSX) has launched a clinical trial to determine whether occipital nerve stimulation (ONS) using the Precision™ System can safely and effectively treat...
-
Jun 28, 2013Transaction to Accelerate Boston Scientific Expansion in Growing Electrophysiology Market
In a move that would significantly boost its capabilities in the fast-growing market for advanced electrophysiology procedures, Boston Scientific Corporation (NYSE:BSX) has entered into a...
-
Jun 26, 2013
The first patient implant of the Boston Scientific Corporation (NYSE: BSX) VITALIO™ pacemaker was performed at ZGT Hengelo in Hengelo, the Netherlands. In addition to a comprehensive suite of...
-
Jun 25, 2013
Boston Scientific Corporation (NYSE: BSX) is launching a new family of pacemakers in Europe. These pacemakers monitor respiration, adjust pacing accordingly, and support insight into the patient?s...
-
Jun 24, 2013Outcomes Follow Recent NICE Guidance Supporting Safety and Effectiveness of Subcutaneous Implantable Defibrillators
The Boston Scientific Corporation (NYSE:BSX) S-ICD® (subcutaneous implantable defibrillator) System showed a significant reduction in major lead-related complications when compared with both...
-
May 28, 2013
Boston Scientific Corporation (NYSE: BSX) presenta i risultati positivi di due studi clinici riguardanti nuove ed innovative tecnologie di stent medicati (DES), che rappresentano opzioni...
-
May 28, 2013Nuovi dati clinici sono stati presentati durante l'EuroPCR nel corso di una Late Breaking Clinical Trial Session e hanno dimostrato risultati positivi in termini di minino rigurgito paravalvolare, a 30 giorni, nei primi 60 pazienti trattati con la valvola Lotus™
Boston Scientific Corporation (NYSE: BSX) presenta i risultati positivi di un'analisi pre-specificata dei primi 60 pazienti arruolati nello studio REPRISE II, che valuta la performance e la...
-
May 27, 2013In einer Late-Breaking-Session des EuroPCR Kongresses wurden neue Daten zum erfolgreichen Einsatz derLotus™-Aortenklappe für die ersten 60 Patienten der REPRISE II Studie vorgestellt. Nach 30 Tagen traten kaum Fälle einer paravalvulären Aorteninsuffizienz auf.
Die Boston Scientific Corporation (NYSE: Adaptive Seal™" zur Minimierung paravalvulärer Lecks. Letztere sind ein Mortalitätsprädiktor. Die Klappe ist repositionierbar und bergbar (vor dem...
-
May 27, 2013
Die Boston Scientific Corporation (NYSE: BSX) hat positive Ergebnisse zweier Studien zur innovativen Technologie medikamentenfreisetzender Stents (DES), die sich als richtungsweisende Behandlungen...